A Phase 4 interventional study of DMARDs and Tocilizumab in Arthritis, Rheumatoid, sponsored by Hoffmann-La Roche. Completed at 9 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-12.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 93rd largest by enrollment, is one of 9 that started in 2013, is one of 32 in phase 4, and was the 68th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 9 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 120th largest by enrollment of the 141 interventional ones that give a count, is one of 14 that started in 2013, is one of 28 in phase 4, and was the 156th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label, single-arm extension study will evaluate the long-term safety of tocilizumab (RoActemra/Actemra) in participants with RA. Participants who have completed the MA21488 (NCT00810199) core study and the ML21530 (NCT00754572) study and who could benefit from the study drug, according to the opinion of the investigator, will receive 8 milligrams per kilogram (mg/kg) of intravenous (IV) tocilizumab every 4 weeks. The anticipated time on study treatment is 104 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 104 weeks. The maximum single dose administered to any participant will be of 800 mg of tocilizumab. Participants may also receive disease-modifying anti-rheumatic drugs (DMARDs) in addition to the tocilizumab treatment in any visit, at the investigator discretion, according to the local prescription information and participant's tolerance.
Drug: DMARDs · Drug: Tocilizumab
DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.
Tocilizumab will be administered at 8 mg/kg IV dose every 4 weeks for 104 weeks
Also known as: RoActemra; Actemra
Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (NSAEs)
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; significant medical event, according to the investigator discretion (e.g., may represent a risk to the participant or may require medical/surgical intervention to prevent one of the outcomes mentioned above).
Time frame: From Baseline up to approximately 2 years
Number of Participants With AEs Leading to Dose Modification or Study Discontinuation
Time frame: From Baseline up to approximately 2 years
Number of Participants With AEs of Special Interest
Adverse events of special interest included following events: Infections (including opportunistic infections); myocardial infarction / acute coronary syndrome; gastrointestinal (GI) perforations and related events; malignancies; anaphylaxis/hypersensitivity reactions; demyelinating disorders; stroke; hemorrhagic events; and hepatic events. Overall number of participants who experienced any of these AEs of special interest was reported.
Time frame: From Baseline up to approximately 2 years
Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)
DAS28 score is a measure of participant's disease activity calculated using tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), participant's global assessment of disease activity (general health \[GH\]) using visual analog scale (VAS), 0 millimeter (mm)=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (erythrocyte sedimentation rate \[ESR\] in millimeters per hour \[mm/hr\]) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28 = \[0.56 multiplied by (\*) square root (√) of TJC28\] plus (+) \[0.28\*√SJC28\]+\[0.70\*the natural logarithm (ln) ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and follow-up (FU) Visit 1 (Week 108), FU Visit 2 (Week 116)
Tender Joint Count (TJC)
An assessment of 28 joints was conducted for tenderness. Joints were assessed and classified as tender/not tender by pressure and joint manipulation after a physical examination. Artificial joints, arthrodesis or fused joints were not taken into consideration for tenderness.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Swollen Joint Count (SJC)
An assessment of 28 joints was conducted for swelling. Joints were assessed and classified as swollen/not swollen by pressure and joint manipulation after a physical examination. Artificial joints, arthrodesis or fused joints were not taken into consideration for swelling.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Global Evaluation of Disease Activity by the Participant Using VAS Score
Participant's global assessment of disease activity was measured on a horizontal 0-100 mm VAS, with 0 mm (left end of the line) described as "inactive disease" (free of symptoms and without symptoms of arthritis) and 100 mm (right end of the line) as "disease maximum activity" (maximum activity of arthritis). The participant marked the line according to their assessment and the distance from the left edge was measured.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Global Evaluation of Disease Activity by the Physician Using VAS Score
Physician global assessment of disease activity was measured on a horizontal 0-100 mm VAS, with 0 mm (left end of the line) described as "inactive disease" (free of symptoms and without symptoms of arthritis) and 100 mm (right end of the line) as "disease maximum activity" (maximum activity of arthritis). The physician marked the line according to their assessment and the distance from the left edge was measured.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Participant's Pain Assessment Using VAS Score
Participant's pain assessment was made on a horizontal 0-100 mm VAS, with 0 mm (left end of the line) described as "no pain" and 100 mm (right end of the line) as "unbearable pain". The participant marked the line according to their assessment and the distance from the left edge was measured.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
The Stanford HAQ-DI is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/personal care, ability to stand-up, eating, walking, hygiene, reaching, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents 'no disability' and 3 represents 'very severe, high-dependency disability'.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Health Assessment Questionnaire (HAQ) Pain VAS Score
The HAQ pain VAS is a measure of pain on a continuous 100 mm scale. Participants were asked to indicate how much pain they had in the past week as a result of their illness on a horizontal line from 0 (no pain) to 100 mm (severe pain).
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
C-Reactive Protein (CRP) Level
CRP is an acute phase reactant and is a measure of inflammation.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
ESR Level
ESR is an acute phase reactant and is a measure of inflammation.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
| Milestone | Tocilizumab |
|---|---|
| Started | 26 |
| Completed | 25 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; significant medical event, according to the investigator discretion (e.g., may represent a risk to the participant or may require medical/surgical intervention to prevent one of the outcomes mentioned above).
| participants | Tocilizumab |
|---|---|
| SAEs | 4 |
| NSAEs | 24 |
| participants | Tocilizumab |
|---|---|
| AEs leading to dose modification | 7 |
| AEs leading to study discontinuation | 1 |
Adverse events of special interest included following events: Infections (including opportunistic infections); myocardial infarction / acute coronary syndrome; gastrointestinal (GI) perforations and related events; malignancies; anaphylaxis/hypersensitivity reactions; demyelinating disorders; stroke; hemorrhagic events; and hepatic events. Overall number of participants who experienced any of these AEs of special interest was reported.
| participants | Tocilizumab |
|---|---|
| Number of Participants With AEs of Special Interest | 0 |
DAS28 score is a measure of participant's disease activity calculated using tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), participant's global assessment of disease activity (general health \[GH\]) using visual analog scale (VAS), 0 millimeter (mm)=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (erythrocyte sedimentation rate \[ESR\] in millimeters per hour \[mm/hr\]) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28 = \[0.56 multiplied by (\*) square root (√) of TJC28\] plus (+) \[0.28\*√SJC28\]+\[0.70\*the natural logarithm (ln) ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity.
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=26) | 2.76 ± 1.19 |
| Week 12 (n=24) | 2.23 ± 0.86 |
| Week 24 (n=25) | 2.43 ± 1.01 |
| Week 36 (n=25) | 2.04 ± 0.85 |
| Week 48 (n=21) | 2.32 ± 1.23 |
| Week 56 (n=24) | 1.82 ± 0.55 |
| Week 68 (n=23) | 2.21 ± 0.84 |
| Week 80 (n=24) | 2.06 ± 0.64 |
| Week 92 (n=24) | 2.23 ± 0.96 |
| Week 104 (n=25) | 1.92 ± 0.93 |
| FU Visit 1 (n=13) | 1.70 ± 1.02 |
| FU Visit 2 (n=24) | 3.21 ± 1.35 |
An assessment of 28 joints was conducted for tenderness. Joints were assessed and classified as tender/not tender by pressure and joint manipulation after a physical examination. Artificial joints, arthrodesis or fused joints were not taken into consideration for tenderness.
| tender joints | Tocilizumab |
|---|---|
| Baseline (n=26) | 2.8 ± 3.6 |
| Week 12 (n=24) | 1.8 ± 2.3 |
| Week 24 (n=25) | 2.0 ± 3.6 |
| Week 36 (n=25) | 1.9 ± 2.5 |
| Week 48 (n=21) | 2.8 ± 3.8 |
| Week 56 (n=24) | 1.1 ± 1.2 |
| Week 68 (n=23) | 2.0 ± 2.6 |
| Week 80 (n=24) | 1.6 ± 2.0 |
| Week 92 (n=24) | 1.5 ± 1.7 |
| Week 104 (n=25) | 1.5 ± 1.8 |
| FU Visit 1 (n=13) | 1.8 ± 3.7 |
| FU Visit 2 (n=24) | 2.8 ± 4.7 |
An assessment of 28 joints was conducted for swelling. Joints were assessed and classified as swollen/not swollen by pressure and joint manipulation after a physical examination. Artificial joints, arthrodesis or fused joints were not taken into consideration for swelling.
| swollen joints | Tocilizumab |
|---|---|
| Baseline (n=26) | 1.4 ± 2.0 |
| Week 12 (n=24) | 1.0 ± 2.0 |
| Week 24 (n=25) | 0.6 ± 1.2 |
| Week 36 (n=25) | 0.9 ± 1.0 |
| Week 48 (n=21) | 1.4 ± 2.5 |
| Week 56 (n=24) | 0.8 ± 1.8 |
| Week 68 (n=23) | 0.9 ± 1.5 |
| Week 80 (n=24) | 0.4 ± 0.8 |
| Week 92 (n=24) | 0.8 ± 1.2 |
| Week 104 (n=25) | 0.6 ± 1.3 |
| FU Visit 1 (n=13) | 0.2 ± 0.4 |
| FU Visit 2 (n=24) | 1.5 ± 2.2 |
Participant's global assessment of disease activity was measured on a horizontal 0-100 mm VAS, with 0 mm (left end of the line) described as "inactive disease" (free of symptoms and without symptoms of arthritis) and 100 mm (right end of the line) as "disease maximum activity" (maximum activity of arthritis). The participant marked the line according to their assessment and the distance from the left edge was measured.
| mm | Tocilizumab |
|---|---|
| Baseline (n=26) | 35.2 ± 25.3 |
| Week 12 (n=26) | 36.4 ± 26.4 |
| Week 24 (n=26) | 38.4 ± 27.2 |
| Week 36 (n=25) | 31.8 ± 25.0 |
| Week 48 (n=23) | 32.8 ± 28.8 |
| Week 56 (n=25) | 30.6 ± 22.7 |
| Week 68 (n=24) | 32.4 ± 24.6 |
| Week 80 (n=24) | 36.1 ± 26.2 |
| Week 92 (n=25) | 36.2 ± 25.5 |
| Week 104 (n=25) | 33.4 ± 25.2 |
| FU Visit 1 (n=15) | 37.1 ± 28.0 |
| FU Visit 2 (n=25) | 42.6 ± 29.9 |
Physician global assessment of disease activity was measured on a horizontal 0-100 mm VAS, with 0 mm (left end of the line) described as "inactive disease" (free of symptoms and without symptoms of arthritis) and 100 mm (right end of the line) as "disease maximum activity" (maximum activity of arthritis). The physician marked the line according to their assessment and the distance from the left edge was measured.
| mm | Tocilizumab |
|---|---|
| Baseline (n=26) | 20.6 ± 18.7 |
| Week 12 (n=26) | 11.4 ± 14.1 |
| Week 24 (n=26) | 13.8 ± 14.7 |
| Week 36 (n=25) | 13.1 ± 10.4 |
| Week 48 (n=23) | 9.1 ± 11.3 |
| Week 56 (n=25) | 13.0 ± 13.3 |
| Week 68 (n=24) | 11.6 ± 11.9 |
| Week 80 (n=24) | 11.3 ± 11.2 |
| Week 92 (n=25) | 13.7 ± 11.7 |
| Week 104 (n=25) | 10.0 ± 9.7 |
| FU Visit 1 (n=15) | 11.7 ± 11.5 |
| FU Visit 2 (n=25) | 15.3 ± 18.4 |
Participant's pain assessment was made on a horizontal 0-100 mm VAS, with 0 mm (left end of the line) described as "no pain" and 100 mm (right end of the line) as "unbearable pain". The participant marked the line according to their assessment and the distance from the left edge was measured.
| mm | Tocilizumab |
|---|---|
| Baseline (n=26) | 31.9 ± 21.7 |
| Week 12 (n=26) | 29.0 ± 25.1 |
| Week 24 (n=26) | 33.7 ± 25.4 |
| Week 36 (n=25) | 28.6 ± 21.5 |
| Week 48 (n=23) | 27.8 ± 25.2 |
| Week 56 (n=25) | 27.4 ± 23.1 |
| Week 68 (n=24) | 27.8 ± 23.1 |
| Week 80 (n=24) | 31.9 ± 24.3 |
| Week 92 (n=25) | 29.5 ± 22.7 |
| Week 104 (n=25) | 28.6 ± 22.6 |
| FU Visit 1 (n=15) | 28.9 ± 25.8 |
| FU Visit 2 (n=25) | 42.6 ± 30.1 |
The Stanford HAQ-DI is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/personal care, ability to stand-up, eating, walking, hygiene, reaching, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents 'no disability' and 3 represents 'very severe, high-dependency disability'.
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=26) | 0.68 ± 0.61 |
| Week 12 (n=26) | 0.49 ± 0.43 |
| Week 24 (n=26) | 0.49 ± 0.38 |
| Week 36 (n=25) | 0.49 ± 0.45 |
| Week 48 (n=23) | 0.48 ± 0.49 |
| Week 56 (n=24) | 0.53 ± 0.60 |
| Week 68 (n=24) | 0.52 ± 0.47 |
| Week 80 (n=24) | 0.53 ± 0.48 |
| Week 92 (n=23) | 0.43 ± 0.44 |
| Week 104 (n=24) | 0.48 ± 0.50 |
| FU Visit 1 (n=15) | 0.56 ± 0.42 |
| FU Visit 2 (n=23) | 0.63 ± 0.59 |
The HAQ pain VAS is a measure of pain on a continuous 100 mm scale. Participants were asked to indicate how much pain they had in the past week as a result of their illness on a horizontal line from 0 (no pain) to 100 mm (severe pain).
| mm | Tocilizumab |
|---|---|
| Baseline (n=26) | 31.9 ± 22.6 |
| Week 12 (n=26) | 30.8 ± 24.5 |
| Week 24 (n=26) | 37.8 ± 26.3 |
| Week 36 (n=25) | 30.1 ± 23.4 |
| Week 48 (n=23) | 32.7 ± 29.4 |
| Week 56 (n=24) | 31.3 ± 24.0 |
| Week 68 (n=24) | 32.9 ± 25.1 |
| Week 80 (n=24) | 34.4 ± 27.2 |
| Week 92 (n=23) | 38.2 ± 30.3 |
| Week 104 (n=24) | 29.0 ± 23.9 |
| FU Visit 1 (n=15) | 30.9 ± 24.8 |
| FU Visit 2 (n=22) | 43.3 ± 32.8 |
CRP is an acute phase reactant and is a measure of inflammation.
| milligrams per deciliter (mg/dL) | Tocilizumab |
|---|---|
| Baseline (n=24) | 0.51 ± 0.91 |
| Week 12 (n=26) | 3.13 ± 6.17 |
| Week 24 (n=25) | 1.08 ± 1.58 |
| Week 36 (n=25) | 2.58 ± 3.00 |
| Week 48 (n=21) | 0.21 ± 0.27 |
| Week 56 (n=24) | 0.41 ± 0.92 |
| Week 68 (n=24) | 0.43 ± 0.74 |
| Week 80 (n=24) | 0.64 ± 1.91 |
| Week 92 (n=23) | 1.86 ± 7.11 |
| Week 104 (n=25) | 0.12 ± 0.16 |
| FU Visit 1 (n=13) | 0.10 ± 0.11 |
| FU Visit 2 (n=24) | 1.46 ± 5.05 |
ESR is an acute phase reactant and is a measure of inflammation.
| mm/hr | Tocilizumab |
|---|---|
| Baseline (n=26) | 9.8 ± 10.2 |
| Week 12 (n=24) | 4.9 ± 3.1 |
| Week 24 (n=25) | 8.5 ± 7.6 |
| Week 36 (n=25) | 4.6 ± 3.2 |
| Week 48 (n=21) | 5.1 ± 4.7 |
| Week 56 (n=24) | 4.9 ± 5.3 |
| Week 68 (n=23) | 6.7 ± 7.2 |
| Week 80 (n=24) | 6.4 ± 9.1 |
| Week 92 (n=24) | 7.5 ± 9.2 |
| Week 104 (n=25) | 5.5 ± 6.3 |
| FU Visit 1 (n=13) | 4.8 ± 5.0 |
| FU Visit 2 (n=24) | 21.9 ± 29.7 |
Collected over From Baseline up to approximately 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab | — | 4/26 (15.4%) | 24/26 (92.3%) |
| Event | Tocilizumab |
|---|---|
| Ischaemic strokeNervous system disorders | 1/26 |
| Total lung capacity decreasedInvestigations | 1/26 |
| Lung disorderRespiratory, thoracic and mediastinal disorders | 1/26 |
| Corneal perforationInjury, poisoning and procedural complications | 1/26 |
| DiverticulitisGastrointestinal disorders | 1/26 |
| Event | Tocilizumab |
|---|---|
| Respiratory tract infection NOSInfections and infestations | 12/26 |
| Musculoskeletal painMetabolism and nutrition disorders | 8/26 |
| Urinary tract infectionInfections and infestations | 7/26 |
| DyslipidaemiaMetabolism and nutrition disorders | 6/26 |
| HeadacheNervous system disorders | 5/26 |
| DyspepsiaGastrointestinal disorders | 4/26 |
| TonsillitisInfections and infestations | 4/26 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 4/26 |
| HypercholesterolemiaMetabolism and nutrition disorders | 3/26 |
| AnxietyPsychiatric disorders | 3/26 |
Intention to treat (ITT) population included all participants who received at least one dose of tocilizumab during the study.
| Age, Continuous(years) | Tocilizumab |
|---|---|
| Mean | 56.0 ± 12.6 |
| Sex: Female, Male(Participants) | Tocilizumab |
|---|---|
| Female | 25 |
| Male | 1 |
Ran from Jan 2013 to primary completion in Jun 2016, 40 months.
Results were first posted in Jun 2017, 1 year after primary completion.
Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 40 months is above that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab